| Key Indicators For Quality Colonoscopy Identified
OAK BROOK, Ill., Sept. 13 /PRNewswire/ -- Defining measurements and identifying quality standards in the delivery of colonoscopic care is a major priority for the nation's leading gastrointestinal endoscopic healthcare association. The American Society for Gastrointestinal Endoscopy (ASGE) recently identified objective measures related to colonoscopy. Using these guidelines and measurements, endoscopists can assess and improve their performance when delivering patient care. "Quality Indicators for Colonoscopy" was published as a supplement to the April 2006 issue of GIE: Gastrointestinal Endoscopy, as part of a collection of quality indicators documents. "Setting quality standards for colonoscopy is a foremost concern for ASGE. These standards will assist in the fight to prevent colon cancer and for successful diagnosis and treatment of a wide variety of digestive health conditions," said Gary W.
Nexavar First FDA-Approved Drug Therapy For Liver Cancer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Nexavar� (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), or liver cancer. Nexavar, an oral anticancer drug, is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease. In 2005 Nexavar became the first new treatment in more than a decade for advanced kidney cancer, and is currently approved in more than 60 countries for this indication. "The approval of Nexavar in liver cancer marks the second time in two years that this novel kinase inhibitor has been granted FDA approval on a Priority Review basis, making it rapidly available to patients who previously had limited treatment options" said Arthur Higgins, chairman of the Executive Committee of Bayer HealthCare.
Prostate Cancer Radiotherapy Won't Affect Sexual Function
MONDAY, Oct. 29 (HealthDay News) High-dose precision radiation therapy doesn't harm the sexual function of prostate cancer patients, U.S. researchers say. A team at Fox Chase Cancer Center in Philadelphia tracked 155 men with intermediate- to high-risk prostate cancer who underwent intensity-modulated radiation therapy (IMRT), a technique that more precisely targets the tumor. "IMRT is revolutionizing how we treat men with prostate cancer, because it improves our ability to avoid normal tissue. As a result, more radiation dose can be delivered to the prostate by increasing the amount of radiation each day. Increasing the radiation used each day is particularly attractive, because it also shortens the treatment time by several days," study lead author Dr. Mark Buyyounouski, attending physician in the radiology department at Fox Chase, said in a prepared statement.
Genta Incorporated to Present at the Acumen BioFin Rodman & Renshaw ...
BERKELEY HEIGHTS, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ: GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and update of corporate activities at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The presentation is scheduled for Tuesday, November 6th at 10:55 am EST at the Palace Hotel, New York, NY. The presentation will be webcast and accessible at the Investor Relations section of the Company's website at: http://www.genta.com/investorrelation/events.html. The presentation will be archived for 30 days. About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.
|
